730 related articles for article (PubMed ID: 25605840)
1. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis.
Teulings HE; Limpens J; Jansen SN; Zwinderman AH; Reitsma JB; Spuls PI; Luiten RM
J Clin Oncol; 2015 Mar; 33(7):773-81. PubMed ID: 25605840
[TBL] [Abstract][Full Text] [Related]
2. Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events.
Chan L; Hwang SJE; Byth K; Kyaw M; Carlino MS; Chou S; Fernandez-Penas P
J Am Acad Dermatol; 2020 Feb; 82(2):311-316. PubMed ID: 31233857
[TBL] [Abstract][Full Text] [Related]
3. Radiation-induced melanoma-associated leucoderma, systemic antimelanoma immunity and disease-free survival in a patient with advanced-stage melanoma: a case report and immunological analysis.
Teulings HE; Tjin EP; Willemsen KJ; Krebbers G; van Noesel CJ; Kemp EH; Nieuweboer-Krobotova L; van der Veen JP; Luiten RM
Br J Dermatol; 2013 Apr; 168(4):733-8. PubMed ID: 23421690
[TBL] [Abstract][Full Text] [Related]
4. Immunological basis of melanoma-associated vitiligo-like depigmentation.
González R; Torres-López E
Actas Dermosifiliogr; 2014 Mar; 105(2):122-7. PubMed ID: 23146137
[TBL] [Abstract][Full Text] [Related]
5. Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy.
Okamoto T; Irie RF; Fujii S; Huang SK; Nizze AJ; Morton DL; Hoon DS
J Invest Dermatol; 1998 Dec; 111(6):1034-9. PubMed ID: 9856813
[TBL] [Abstract][Full Text] [Related]
6. New perspectives on the role of vitiligo in immune responses to melanoma.
Byrne KT; Turk MJ
Oncotarget; 2011 Sep; 2(9):684-94. PubMed ID: 21911918
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for the management of advanced melanoma: the next steps.
Zikich D; Schachter J; Besser MJ
Am J Clin Dermatol; 2013 Aug; 14(4):261-72. PubMed ID: 23516145
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of spontaneous antibody responses against tumor-associated antigens in malignant melanoma patients.
Zörnig I; Halama N; Lorenzo Bermejo J; Ziegelmeier C; Dickes E; Migdoll A; Kaiser I; Waterboer T; Pawlita M; Grabe N; Ugurel S; Schadendorf D; Falk C; Eichmüller SB; Jäger D
Int J Cancer; 2015 Jan; 136(1):138-51. PubMed ID: 24839182
[TBL] [Abstract][Full Text] [Related]
9. Correlation between cutaneous adverse events and prognosis in patients with melanoma treated with nivolumab: A single institutional retrospective study.
Nakano E; Takahashi A; Namikawa K; Muto Y; Jinnai S; Kage Y; Mizuta H; Tsutsumida A; Yamazaki N
J Dermatol; 2020 Jun; 47(6):622-628. PubMed ID: 32162349
[TBL] [Abstract][Full Text] [Related]
10. Metastatic melanoma: spontaneous occurrence of auto antibodies is a good prognosis factor in a prospective cohort.
Maire C; Vercambre-Darras S; Devos P; D'Herbomez M; Dubucquoi S; Mortier L
J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):92-6. PubMed ID: 22145691
[TBL] [Abstract][Full Text] [Related]
11. Regression of nevi, vitiligo-like depigmentation and halo phenomenon may indicate response to immunotherapy and targeted therapy in melanoma.
Farinazzo E; Zelin E; Agozzino M; Papa G; Pizzichetta MA; di Meo N; Zalaudek I
Melanoma Res; 2021 Dec; 31(6):582-585. PubMed ID: 34433200
[TBL] [Abstract][Full Text] [Related]
12. Vitiligo-like depigmentation and morpheas after specific intralymphatic immunotherapy for malignant melanoma.
Lacour JP; Caldani C; Thyss A; Schneider M; Ortonne JP
Dermatology; 1992; 184(4):283-5. PubMed ID: 1498395
[TBL] [Abstract][Full Text] [Related]
13. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.
Rosenberg SA; White DE
J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):81-4. PubMed ID: 8859727
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes.
Freeman-Keller M; Kim Y; Cronin H; Richards A; Gibney G; Weber JS
Clin Cancer Res; 2016 Feb; 22(4):886-94. PubMed ID: 26446948
[TBL] [Abstract][Full Text] [Related]
15. Melanoma as a model tumour for immuno-oncology.
Maio M
Ann Oncol; 2012 Sep; 23 Suppl 8():viii10-4. PubMed ID: 22918922
[TBL] [Abstract][Full Text] [Related]
16. Vitiligo and Melanoma-Associated Vitiligo: Understanding Their Similarities and Differences.
Cohen BE; Manga P; Lin K; Elbuluk N
Am J Clin Dermatol; 2020 Oct; 21(5):669-680. PubMed ID: 32468356
[TBL] [Abstract][Full Text] [Related]
17. Case Report: Immune checkpoint inhibitor-related vitiligo-like depigmentation in non-melanoma advanced cancer: A report of three cases and a pooled analysis of individual patient data.
Rao H; Guo Z; Wen X; Zeng X; Wu L; Huang L
Front Oncol; 2022; 12():1099108. PubMed ID: 36713515
[TBL] [Abstract][Full Text] [Related]
18. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.
Lotem M; Machlenkin A; Hamburger T; Nissan A; Kadouri L; Frankenburg S; Gimmon Z; Elias O; David IB; Kuznetz A; Shiloni E; Peretz T
Clin Cancer Res; 2009 Aug; 15(15):4968-77. PubMed ID: 19602547
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ;
J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000
[TBL] [Abstract][Full Text] [Related]
20. Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study.
Quaglino P; Marenco F; Osella-Abate S; Cappello N; Ortoncelli M; Salomone B; Fierro MT; Savoia P; Bernengo MG
Ann Oncol; 2010 Feb; 21(2):409-414. PubMed ID: 19622589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]